Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.62 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552784 | 0.89 | AKR1C3 (0.67) | NR4A2SRD5A2MRGPRX4AKR1C3NPC1 | |
| SCHEMBL8922344 | 0.88 | SRD5A2 (0.53) | NR4A2SRD5A2MAPK14MRGPRX4AKR1C3 | |
| SCHEMBL11071994 | 0.86 | MAOB (0.63) | MAPK14CHEK2CYP2C9RAB9ATLR8 | |
| SCHEMBL693337 | 0.86 | MAPK14 (0.54) | NR4A2MAPK14MRGPRX4CHEK2TLR8 | |
| SCHEMBL27579381 | 0.85 | LTA4H (0.59) | MAPK14POLBCYP2C9TLR8TLR7 | |
| SCHEMBL4742580 | 0.84 | AKR1C3 (0.70) | NR4A2MAPK14MRGPRX4AKR1C3NPC1 | |
| SCHEMBL11073452 | 0.84 | MAPK14 (0.51) | NR4A2SRD5A2MAPK14MRGPRX4NPC1 | |
| SCHEMBL10656423 | 0.84 | MAPK14 (0.59) | NR4A2MAPK14MRGPRX4CHEK2TLR8 | |
| SCHEMBL694268 | 0.84 | MAPT (0.61) | MAPK14CHEK2POLBRAB9ATLR8 | |
| SCHEMBL11078518 | 0.84 | MAPK14 (0.52) | NR4A2MAPK14MRGPRX4CHEK2TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5219477-A | Containing organometallic salts and inorganic metal borates; fromo reactinmetal hydroxide with phenols or aromatic carboxylic acid | THE DOW CHEMICAL COMPANY (US) | 1993-06-15 | — | — | US | claimed |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-2785707-B1 | NOVEL 2H-INDAZOLES AS EP2 RECEPTOR ANTAGONISTS | BAYER IP GMBH (DE) | 2018-01-24 | — | — | EP | disclosed |
| EP-2773352-B1 | 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS | RES TRIANGLE INST (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9655887-B2 | Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9512105-B2 | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160089364-A1 | PHARMACEUTICAL COMPOSITION AND THE USE THEREOF, AND APPLICATION REGIME OF SAID PHARMACEUTICAL COMPOSITION FOR ON-DEMAND CONTRACEPTION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | US | disclosed |
| US-9062041-B2 | 2H-indazoles as EP2 receptor antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| WO-2007044410-A1 | PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20060094706-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2006-05-04 | — | — | US | disclosed |
| EP-1511751-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | Neogenesis Pharmaceuticals, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | NEOGENESIS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003101993-A1 | PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| US-5456848-A | Oxidation resistance | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1995-10-10 | — | — | US | disclosed |
| US-5219477-A | Containing organometallic salts and inorganic metal borates; fromo reactinmetal hydroxide with phenols or aromatic carboxylic acid | THE DOW CHEMICAL COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | RNGTT, PNP, ZC3HAV1 | NR4A2 3781/4885SRD5A2 2089/4885MAPK14 3581/4885 |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | NR4A2 4745/4885SRD5A2 4796/4885MAPK14 1014/4885 |
| US-20160089364-A1 | PHARMACEUTICAL COMPOSITION AND THE USE THEREOF, AND APPLICATION REGIME OF SAID PHARMACEUTICAL COMPOSITION FOR ON-DEMAND CONTRACEPTION | PTGER2, PTGER3, PTGER1 | NR4A2 849/4885SRD5A2 103/4885MAPK14 2470/4885 |
| US-20060094706-A1 | Pyrazolopyrimidines as protein kinase inhibitors | CDKN1A, EIF2AK2, DCK | NR4A2 3882/4885SRD5A2 3594/4885MAPK14 925/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | NR4A2 4745/4885SRD5A2 4796/4885MAPK14 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.